Search results “David sabatini cancer research”
Signaling Pathways in Cancer Symposium: David Sabatini
David Sabatini Whitehead Institute “Growth By The mTOR Pathway” https://ki.mit.edu/news/pathways/2012
Views: 3799 KochInstituteMIT
Dr. David Sabatini's Research on the mTOR Pathway
The FNIH selected David M. Sabatini, M.D., Ph.D., as the recipient of the 5th annual Lurie Prize in Biomedical Sciences for discovery of the mTOR (mechanistic target of rapamycin) cellular pathway as a key regulator of growth and metabolism in response to nutrients. Learn about Dr. Sabatini's work on nutrient sensing and the impact of caloric restriction on health and lifespan. Dr. Sabatini is a Member of the Whitehead Institute for Biomedical Research, a Professor of Biology at the Massachusetts Institute of Technology and an Investigator of the Howard Hughes Medical Institute.
Views: 1993 FNIH
2011 KI Symposium: David Sabatini (Part 1 of 2)
Part 1 of David Sabatini's talk, "mTOR Signaling and Cancer Metabolism," presented at the 2011 Koch Institute Summer Symposium.
Views: 5089 KochInstituteMIT
2011 KI Symposium: David Sabatini (Part 2 of 2)
Part 2 of David Sabatini's talk, "mTOR Signaling and Cancer Metabolism," presented at the 2011 Koch Institute Summer Symposium.
Views: 1946 KochInstituteMIT
2016 Killian Lecture: Tyler Jacks, "Unlocking the Secrets of Cancer"
Lecture title: "Unlocking the Secrets of Cancer" Tyler Jacks, the David H. Koch professor of biology and director of the Koch Institute for Integrative Cancer Research, was MIT’s James R. Killian Jr. Faculty Achievement Award winner for 2015–2016. A pioneering cancer biologist, Professor Jacks was recognized by the committee for his influence on the field of cancer research and for his leadership of MIT’s multidisciplinary cancer research community. Thursday, February 11, 2016 4 pm Huntington Hall (10-250)
Views: 1413 MIT Institute Events
2015 Whitehead Symposium :: Cancer: Treating the "Untreatable"
David Sabatini, Member, Whitehead Institute "Cancer: Treating the "Untreatable" Part II"
2011 Summer Symposium: David Sabatini
mTOR signaling and cancer metabolism David Sabatini, Whitehead Institute https://ki.mit.edu/news/symposium/2011
Views: 203 KochInstituteMIT
David Sabatini, Ph D , M D , Growth By The mTOR Pathway
David Sabatini, Ph.D., M.D. of the Whitehead Institute at MIT discussed his work defining the role of mTOR in the amino acid sensing pathway.
Clevers H (2015): Wnt signaling, Lgr5 stem cells, organoids and cancer
Walter and Eliza Hall Institute Centenary Scientific Symposium 31 July 2015 Session 9: Cancer Professor Hans Clevers Hubrecht Institute, Netherlands
Views: 16804 WalterandElizaHall
81st Symposium - Targeting Cancer - David Tuveson
2016 Cold Spring Harbor Laboratory Symposium on Quantitative Biology Targeting Cancer Interview with David Tuveson Cold Spring Harbor Laboratory, NY Interviewer: Gemma Alderton Nature Reviews Cancer, London, UK Attend a CSHL meeting: http://bit.ly/cshlmtg Train at a CSHL course: http://bit.ly/cshlcourses Subscribe to receive new video notifications: http://bit.ly/2aVrXaM CONNECT WITH US Blog: http://bit.ly/cshlcxblog Twitter: http://bit.ly/cshlmctwitter Instagram: http://bit.ly/cshlmcinsta Facebook: http://bit.ly/cshlmcfb Website: http://bit.ly/cshlmtgcrs
Views: 1008 CSHL Leading Strand
Dr. David Tuveson on World Pancreatic Cancer Day
Why is World Pancreatic Cancer Day important? Let Dr. David Tuveson, Director of the Lustgarten Foundation Pancreatic Cancer Research Laboratory and Professor at Cold Spring Harbor Laboratory, explain.
Dr. David Sabatini - Conferencia IDIBELL 2012, Barcelona.
El Dr. David Sabatini habla con ecancer en la Conferencia de IDIBELL en Medicina Personalizada. Explica el uso de la rapimicina y su implicación en el sistema de "MTor Pathway". Para mayor información visite http://www.ecancerlatinoamerica.org
Signaling Pathways in Cancer Symposium: Michael Yaffe
Michael Yaffe David H. Koch Institute for Integrative Cancer Research at MIT “Harnessing Cross-Talk Between Signaling Pathways to Improve Cancer Treatment” https://ki.mit.edu/news/pathways/2012
Views: 328 KochInstituteMIT
3rd de Duve Lecture - D. Sabatini: mTOR and lysosomes in growth control
given by Prof. David Sabatini (Cambridge, MA, USA) on March 1, 2018
Views: 551 de Duve Institute
Regulation of growth by the mTOR pathway
Regulation of growth by the mTOR pathway Air date: Wednesday, March 20, 2013, 3:00:00 PM Wednesday Afternoon Lecture Series The mammalian target of rapamycin (mTOR), the target of the immunosuppressive drug rapamycin, is the central component of a nutrient- and hormone-sensitive signaling pathway that regulates cell growth and proliferation. This pathway becomes deregulated in many human cancers and plays an important role in the control of metabolism and aging. Sabatini's lab has identified two distinct mTOR-containing proteins complexes, one of which regulates growth through S6K and another that regulates cell survival through Akt. These complexes, mTORC1 and mTORC2, define both rapamycin-sensitive and insensitive branches of the mTOR pathway. New results on the regulation and functions of the mTORC1 and mTORC2 pathways will be discussed. Author: David M. Sabatini, M.D., Ph.D., MIT Runtime: 00:59:04 Permanent link: http://videocast.nih.gov/launch.asp?17962
Views: 44574 nihvcast
ROBERT A. WEINBERG, PhD - EMT, Cancer Stem Cells and the Mechanisms of Malignant Progression
Winner of the Salk Institute Medal for Research Excellence An internationally recognized authority on the genetic basis of human cancer, Robert A. Weinberg is a founding member of the Whitehead Institute for Biomedical Research and the Daniel K. Ludwig Professor for Cancer Research at the Massachusetts Institute of Technology (MIT). In 1992, he earned the Gairdner Foundation International Award for Achievements in Medical Science. He is also a recipient of the National Medal of Science, the Wolf Prize and the Breakthrough Prize in Life Sciences. He is the first Director of the Ludwig Cancer Center at MIT. Over the past three decades, Weinberg has made breakthrough discoveries in the molecular and genetic roots of cancers. His lab discovered the first oncogene in 1982 and the first tumor suppressor gene in 1986. Most recently, Weinberg and his colleagues were the first to define the genetic hallmarks that a normal human cell must acquire to be transformed into a human cancer cell.
Views: 9088 Salk Institute
The Future of Cancer Prevention and Treatment
Leading cancer researcher Dr. Lewis Cantley, director of the newly established Cancer Center at Weill Cornell Medical College and NewYork-Presbyterian Hospital, delivers the annual Racker Lecture, November 15, 2012.
Views: 2614 Cornell University
2015 Whitehead Symposium :: Cancer: Treating the "Untreatable"
Lyerka Miller introduces Whitehead Director David C. Page
30. Cancer 2
MIT 7.013 Introductory Biology, Spring 2011 View the complete course: http://ocw.mit.edu/7-013S11 Instructor: Tyler Jacks In this lecture, Professor Jacks discusses the genes and mutations involved in the development of cancer, how to find them, and why they are important. License: Creative Commons BY-NC-SA More information at http://ocw.mit.edu/terms More courses at http://ocw.mit.edu
Views: 13346 MIT OpenCourseWare
2013 Bridge Project Roundtable: Cancer Treatment Challenges
At this May 6, 2013 event, cancer biologists, engineers, and clinicians gathered at the Koch Institute at MIT for an open discussion of the greatest challenges and most promising solutions in cancer care. To learn more about the Bridge Project, a collaboration between the Koch Institute and the Dana-Farber/Harvard Cancer Center, visit http://ki.mit.edu/approach/bridge.
Views: 558 KochInstituteMIT
2015 Whitehead Symposium :: Cancer: Treating the "Untreatable"
Hazel Sive, Member, Whitehead Institute "An Introduction to the Importance of Basic Research"
“The Where and Why of the mTOR pathway”
Brian Kennedy, PhD Professor Buck Institute for Research on Aging Novato, CA Lecture: “The Where and Why of the mTOR pathway”
Essay Winner Highlights Importance of Communication in Science
Liron Bar-Peled, winner of the 2014 Science and SciLifeLab Grand Prize for his essay "Size Does Matter," speaks on the importance of communication in science and his work at The Scripps Research Institute (TSRI)—basic research with relevance to cancer. Bar-Peled, whose essay grew out of his graduate work in the lab of David Sabatini at MIT, is currently Lallage Feazel Wall Fellow of the Damon Runyon Cancer Research Foundation at TSRI. Click [CC] in video viewer to access Closed Captions and Subtitles on any of our videos.
Conquering Cancer: Personalized Cancer Care
Session Chair: Michael B. Yaffe, David H. Koch Institute for Integrative Cancer Research at MIT; Professor, Departments of Biology and Biological Engineering, MIT; Senior Associate, Broad Institute Panel: Daniel A. Haber SB '77 SM '77, Director, Massachusetts General Hospital Cancer Center; Isselbacher/Schwartz Professor, Harvard Medical School; Investigator, Howard Hughes Medical Institute Michael T. Hemann, David H. Koch Institute for Integrative Cancer Research at MIT; Latham Family Career Development Assistant Professor of Biology, MIT David M. Livingston, Emil Frei Professor of Genetics and Medicine, Harvard Medical School; Deputy Director, Dana-Farber/Harvard Cancer Center; Chief, Charles A. Dana Division of Human Cancer Genetics Corbin Elizabeth Meacham, G, David H. Koch Institute for Integrative Cancer Research at MIT; Department of Biology, MIT
2015 Whitehead Symposium :: Cancer: Treating the "Untreatable"
Richard Young, Member, Whitehead Institute "Cancer: Treating the "Untreatable" Part I"
Whitehead Institute: How to boost the efficacy of the chemotherapy drug methotrexate
Naama Kanarek, a postdoctoral researcher in the lab of Whitehead Member David Sabatini, explains how new genetic tools are allowing insights into the sensitivity of cancer cells to methotrexate.
Tyler Jacks, Director, David H. Koch Institute for Integrative Cancer Research
2008 Koch Institute Symposium: Introduction given by the Institute's Director Tyler Jacks.
Views: 691 KochInstituteMIT
The Human Genome: Collaboration is the New Competition | Dr. David Haussler | TEDxSantaCruz
Dr. David Haussler shares the compelling story about the race between private and public entities to complete the first DNA sequencing of the human genome. What is the significance of providing the world with the first open source sequenced genome and the accompanying Genome Browser tool? Only the opportunity for scientists and medical professionals around the globe to collaborate in ways that are producing gene therapies previously thought impossible... and more. David Haussler is scientific director of the UC Santa Cruz Genomics Institute and director of the Center for Biomolecular Science and Engineering. His work has spawned a cancer research project, a project to map the genome of 10,000 animal species, and programs in computer science, mathematics, microbiology, and medical research. He has a private firm, Five3 Genomics, and is a leader in a global alliance of 70 organizations to fight disease via sharing of genomics and clinical data. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx
Views: 14104 TEDx Talks
Killing cancer cells by targeting glucose metabolism
Cristina Muñoz Pinedo. Cell Death Regulation Group IDIBELL (Institut d'Investigació Biomèdica de Bellvitge) Oncogenic transformation promotes metabolic changes which makes tumors "addicted" to certain metabolites. For this reason, inhibition of tumor metabolism is a promising new therapeutic approach. However, little is known about how metabolic stress triggers tumor cell death. Glucose depletion has been shown to kill cells either by necrosis (non-apoptotic, pro-inflamatory cell death) or by the mitochondrial pathway of apoptosis. Our studies indicate that several tumor cell lines of different origins die in a non-apoptotic manner when deprived of glucose. However, we have recently described an atypical apoptotic pathway engaged in cells from solid tumors. Surprisingly, apoptosis induced by glucose deprivation is independent of the Bcl-2-regulated mitochondrial pathway. We will describe this apoptotic pathway mediated by caspase-8, which is the initiator caspase engaged by death receptors of the TNF family. 2-deoxyglucose is a non-metabolizable glucose analog which competes with glucose and has shown anti-tumor effects in animals. Moreover, this compound is been tested in clinical trials. We are currently studying sensitivity of tumor cells, especially sarcoma cell lines, to 2-deoxyglucose. Interestingly, 2-deoxyglucose promoted apoptosis in cell lines in which glucose deprivation promoted necrosis, suggesting different death mechanisms. 2-deoxyglucose activates the mitochondrial apoptotic pathway and regulates several apoptotic proteins in p53-deficient cells. We found death under normoxia to be associated to endoplasmic reticulum stress rather than lack of ATP. We will discuss the signaling pathways involved in responses to nutritional stress and how to improve sensitivity of tumor cells to metabolic targeting.
The PI3K Signaling Pathway
Genentech BioOncology is currently conducting research on how PI3K Kinase signaling pathway is critical to cell survival and cell growth. Learn how the PI3K pathway involves an intricate signaling cascade that is among the most frequently activated pathways in cancer.
Views: 63011 Genentech
2012 Koch Institute Symposium: Laurie Boyer
"Dynamic and Coordinated Regulation of Developmental Transitions in the Cardiac Lineage," a talk presented by Laurie Boyer at the 2012 Koch Institute Summer Symposium on Epigenetics, Plasticity and Cancer. http://ki.mit.edu/news/symposium
Views: 708 KochInstituteMIT
Koch Institute Image Awards Winner: Kara Cerveny
Kara Cerveny discusses her image, "Sunrise in the Eye: The Making of a Retina," one of ten winners of the 2011 Koch Institute Image Awards. See the image at: http://ki.mit.edu/galleries/2011/cerveny.
Views: 596 KochInstituteMIT
W4L Prof David Tuveson
Views: 342 ASGBI Surgeons
2016 Whitehead Symposium: Part 2
Keynote by Rudolf Jaenisch, PhD
Signaling Pathways in Cancer Symposium:  William Kaelin
William Kaelin Dana Farber Cancer Institute “The VHL Tumor Suppressor Protein: Insights into Oxygen Sensing and Cancer Metabolism” https://ki.mit.edu/news/pathways/2012
Views: 678 KochInstituteMIT
2010 KI Symposium: David Tuveson (Part 1 of 3)
Part 1 of David Tuveson's talk, "Oncogenic Kras: Models and Medicines," presented at the 2010 Koch Institute Summer Symposium. http://ki.mit.edu
Views: 677 KochInstituteMIT
2017 Whitehead Symposium: Part 1
Welcome and State of the Institute by David C. Page, MD, Director, Whitehead Institute
Submitted by Mishael Khan
2010 KI Symposium: Eric Lander (Part 2 of 3)
Part 2 of Eric Lander's talk, "The Human Genome and Cancer," presented at the 2010 Koch Institute Summer Symposium. http://ki.mit.edu
Views: 1131 KochInstituteMIT
Black Cat by D. Sabatini at Sister Wicked Open Mic, Sept 2017
Black Cat, an original by David Sabatini performed at Sister Wicked Open Mic, Sept 30, 2017
"The Intimate Connection Between Cancer, Aging, Protein, and TOR" Ron Rosedale, MD
Dr. Ron Rosedale is an internationally known expert in nutritional and metabolic medicine and was one of the founders of the "low-carb" movement 2 decades ago and perhaps the first to specifically recommend a high fat rather than high-protein, low-carb diet. He has been a pioneer in applying concepts based on the biology of aging to reverse its chronic diseases including diabetes and heart disease by using a unique nutritional approach to improve cellular responses to insulin, leptin, and mTOR. For more information: Physicians for Ancestral Health: ancestraldoctors.org Dr. Rosedale: DrRosedale.com
Dr. Cantley on Lipid That Links Insulin Signaling to Cancer
Lewis Cantley, PhD, director, Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College and NewYork-Presbyterian Hospital, 2017 Giant of Cancer Care® in Scientific Advances, discusses research he was involved in with a lipid that ended up being linked with insulin signaling in cancer.
Views: 152 OncLiveTV
Inhibition of mTOR with nutrition and NAC
UPDATED VIDEOS and CLINICAL PROTOCOLS: -- Digital ebook: https://www.amazon.com/dp/B01KMZZLAQ/ -- Printed Protocols: http://bit.ly/InflamMastery4thEd -- Large PDF sample with photos: http://inflammationmastery.com/edition4/photos.pdf -- Nutrition and Functional Medicine: http://bit.ly/AmazonICHNFM ============================================= Ebooks via the free Kindle software for phones, iPad, and computers: -- Diet: https://www.amazon.com/dp/B01FYCUTHW Now available for $1 -- Migraine: https://www.amazon.com/dp/B01AS15XZW -- Fibromyalgia: https://www.amazon.com/dp/B01AS1ZKPA -- Antiviral Immune Nutrition: https://www.amazon.com/dp/B00OPJXMTS -- mTOR: https://www.amazon.com/dp/B00TVT5YK2/ -- Mitochondrial nutrition: https://www.amazon.com/dp/B00PGA3YJ8
2010 KI Symposium: James Collins (Part 1 of 3)
Part 1 of James Collins' talk, "A Network Biology Approach to Cancer," presented at the 2010 Koch Institute Summer Symposium. http://ki.mit.edu
Views: 233 KochInstituteMIT
2013 Summer Symposium: Dane Wittrup
Synergism Between Antibody and T Cell-Mediated Cancer Immunotherapy K. Dane Wittrup Associate Director, Koch Institute for Integrative Cancer Research Carbon P. Dubbs Professor of Chemical Engineering and Bioengineering Massachusetts Institute of Technology https://ki.mit.edu/news/symposium/2013
Views: 156 KochInstituteMIT
2010 KI Symposium: Julian Downward (Part 2 of 3)
Part 2 of Julian Downward's talk, "RAS and PI 3-kinase Signaling Networks in Cancer," presented at the 2010 Koch Institute Summer Symposium. http://ki.mit.edu
Views: 198 KochInstituteMIT